The Fool has written over 100 articles on Pacific Biosciences of California. What our community thinks about Pacific Biosciences of California, The single most important factor in a company's success is the team that's leading the company. Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina. At that level they are trading at 35.2% premium to the analyst consensus target price of 0.00. According to the CMA, Illumina holds around 80% of the global market share in this area, and 90% in the UK. What our community thinks about Pacific Biosciences of California. The Bottom Line Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. On the product front, this fall PacBio announced the Sequel IIe, which extends the existing Sequel II instrument with on-board computation. Figure 3-2 Product Market Share, 2020 Figure 3-3: Product Market Share, 2025 5. In 2015 Pacific Biosciences launched its new Sequel system based on SMRT technology. Finding stocks with the p... Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. Despite the market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. PACB earnings call for the period ending March 31, 2020. $37.42, giving the company a market capitalisation of Market … The growth can be attributed to … DNA sequencing is a highly concentrated industry and Illumina holds an approximately 80% share of the market globally and 90% in the UK. She added 7 million shares of Pacific Biosciences of California, raising its weighting to 7.1% from 5.6%, and boosted Twist Bioscience by 1.4 million shares, pushing its weighting to 5.9% from 4.7%. Revenues reflectNorth America segment decrease of 25% to $25.2M, AsiaPacific segment decrease of 18% to $14.6M. Investors liked the pricing of the company's secondary stock offering. Pacific Biosciences of California (PACB) Q2 2020 Earnings Call Transcript, Pacific Biosciences of California Inc (PACB) Q1 2020 Earnings Call Transcript, Pacific Biosciences of California Inc (PACB) Q4 2019 Earnings Call Transcript, Here’s Why Illumina Shares Barely Budged When It Gave Up On Its Takeover to The Tune Of $98 Million, About to Buy Penny Stocks? 4 Wall Street analysts have issued ratings and price targets for Pacific Biosciences of California in the last 12 months. PacBio estimates that 10 million human genetic sequences will be conducted annually by 2025 and that one day, the technology will become a routine part of healthcare. $37.42 $37.42 It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. PACB earnings call for the period ending September 30, 2020. BlackRock Institutional Trust Company, N.A. COVID-19 Impact on Global RNA-Seq Market Size, Status and Forecast 2020 The Global RNA-Seq Market Research Report 2021-2026 is a valuable source of insightful data for business strategists. Announces Preliminary Fourth Quarter 2020 Revenue. 1 Look At These 2 Companies First, Here's Why Pacific Biosciences Gained as Much as 10.5% Today, Why Pacific Biosciences of California Stock Is Sinking Today, Here's Why Pacific Biosciences Is Tumbling Today, Why Pacific Biosciences of California Stock Is Skyrocketing Today, Why Pacific Biosciences Fell By 10.6% Earlier Today, Here's Why Pacific Biosciences Tumbled 10% Today, Here's Why Pacific Biosciences of California, Inc. Rose 40.3% in June, Copyright, Trademark and Patent Information. Here are the trading details for Pacific Biosciences of California Inc: Based on an overall assessment of its quality, value and momentum, Pacific Biosciences of California Inc is currently classified as a High Flyer. The DNA sequencing leader announced upgrades to some of its core offerings. If PacBio can build the business such that it secures $250 million in revenue in 2023 and $500 million in 2027, I believe the standalone value is in the range of $6 to $7 per share. The classification is based on a composite score that examines a wide range of fundamental and technical measures. This share price information is delayed by 15 minutes. Illumina just proposed the nuclear option to earn regulatory approval for its merger and keep its biggest competitor at bay. An important predictor of whether a stock price will go up is its track record of momentum. The DNA sequencing leader moved forward in its quest to acquire Pacific Biosciences -- and Wall Street approved. The question now for investors is whether that price strength will continue. and the price has moved by CAPS Rating . PACB earnings call for the period ending December 31, 2019. Illumina's offer of $8 per share represented a 71% premium over PacBio's 30-trading-day volume-weighted average share price as of the market close on Oct. 31, 2018. DNA Sequencing Market Overview: The global DNA sequencing market was valued at $6,243 million in 2017, and is expected to reach $25,470 million in 2025, registering a CAGR of 19.0% from 2018 to 2025. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. The Competition and Markets Authority (CMA) has been investigating the proposed $1.2 billion merger of Illumina, Inc. (Illumina) and Pacific Biosciences of California, Inc (PacBio… : For the nine months ended 30 September 2020, PacificBiosciences of California Inc revenues decreased 18% to$51.8M. Share to Facebook; Share to Twitter ... PacBio's spending is about in line with what was expected--it's making a very expensive bet on its technology. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. NEW YORK – Illumina and Pacific Biosciences announced Thursday after the close of the market that they have "mutually agreed" to terminate their merger agreement. Market data powered by FactSet and Web Financial Group. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Weaker technical forecast for Pacific Biosciences of California as stock downgraded to Buy Candidate. You can read more about the power of momentum in assessing share price movements on Stockopedia. The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales. At the current price of $37.42, shares in Pacific Biosciences of California Inc are trading at 0.250k% against their 200 day moving average. Primary metrics and data points about Pacific Biosciences of California. 78 Outperform. PacBio’s share price is trading between $5.00-5.50 these days, much below Illumina’s offer of $8.00 per share. Pacific Biosciences of California Inc View which stocks have been most impacted by COVID-19. Investors are enthusiastic about an analyst's upgrade of the stock. market position, the CMA also took into account, within the context of the dynamic nature of the market, the evidence that PacBio’s current share of supply does not accurately reflect its competitive significance following the launch of its Sequel II instrument in April 2019. Global Third-Generation Sequencing Market Size, Status and Forecast 2020-2026. Going it alone might be a better bet for the company and investors. In terms of relative price strength - which takes into account the overall market trend - the Pacific Biosciences of California Inc price has moved by £5.09bn. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives. IIe's built-in silicon can rapidly compute the HiFi reads that are clearly where PacBio thinks the market excitement is, eliminating the requirement (and complexity) to transfer raw data off the instrument to a cluster and then compute a consensus. per Employee $224.98K; P/E Ratio N/A; EPS-$0.28; Yield N/A; Dividend N/A; Ex … Of the analysts with advisory recommendations for Pacific Biosciences of California Inc, there are there are currently 0 "buy" , 3 "hold" and 0 "sell" recommendations. Pacific Biosciences of California, Inc. Common Stock (PACB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. Market Cap: $7B: Company Rating. The deal, announced in November 2018, would have seen Illumina acquire PacBio for $8 per share — approximately $1.2 billion in cash. Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. At the current price of $38.59, shares in Pacific Biosciences of California Inc are trading at 0.295k% against their 200 day moving average. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. We were not able to find PE ratio data for Pacific Biosciences of California Inc. Pacific Biosciences of California Inc's management team is headed by: Here are the top five shareholders of Pacific Biosciences of California Inc based on the size of their shareholding: © Stockopedia 2021, Refinitiv, Share Data Services. Investors are taking a cautious stance ahead of earnings next week and an ongoing trade spat with China. Shares in Pacific Biosciences of California Inc are currently trading at The global NGS market size was valued at $4,533 million in 2018, and is estimated to reach $18,565 million by 2026, growing at a CAGR of 19.2% from 2019 to 2026.NGS is a technology in which millions and billions of DNA strands can be sequenced through massive parallelization. You can view the full broker recommendation list by unlocking its StockReport. Why Pacific Biosciences of California Hit a Speed Bump With Its Q3 Results, Pacific Biosciences of California (PACB) Q3 2020 Earnings Call Transcript, Why Pacific Biosciences of California Stock Jumped Today, Why Pacific Biosciences of California Shares Are Soaring Today. Their average twelve-month price target is $16.00, predicting that the stock has a possible downside of 38.32%. The question now for investors is whether that price strength will continue. Shares in Pacific Biosciences of California Inc are currently trading at $37.42, giving the company a market capitalisation of £5.09bn. What's Behind Pacific Biosciences of California's Ugly Q2 Results? PACB earnings call for the period ending June 30, 2020. 25 Underperform. The report presents an in-depth assessment of the Third-Generation Sequencing Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles … You can read more about the power of momentum in assessing share price movements on Stockopedia. 0.656k% over the past 365 days. Next Generation Sequencing (NGS) Market Outlook - 2026. DNA sequencing giant Illumina dropped a deal that would have brought it complementary technology. The firm lost $102 million in 2018 and $92 million … It has provisionally concluded that the merger between Illumina and PacBio will cause a loss of competition between the two companies, and lead to fewer … Net loss decreased 46% to $45.5M. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software. The genetic disease testing segment held nearly 25% market share in 2019 and will witness substantial growth over the forecast period. The CMA’s investigation has found that PacBio … Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Pacific Biosciences has rivaled Illumina in technology, yet it is a questionable market threat. The question now for investors is whether that price strength will continue. To buy shares in Pacific Biosciences of California Inc you'll need a share-dealing account with an online or offline stock broker. 1305 O'brien Drive, MENLO PARK, 94025, United States, BUZZ-Pacific Biosciences: Rises on gene sequencing deal with Invitae Corp, Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform, Pacific Biosciences Grants Equity Incentive Awards to New Employees, BRIEF-Pacific Biosciences Of California Inc Announces Preliminary Fourth Quarter 2020 Revenue, Pacific Biosciences of California, Inc. Stock analysis for Pacific Biosciences of California Inc (PACB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. are trading at The gene sequencing company plans to tap investors for more cash. 0.547k% over the past year. Pacific Biosciences is a leader in the latest generation of human DNA sequencing. The merger with PacBio would have given it an almost 100 per cent market share in the UK. Lower net lossreflects Other Sales, general and administrative decreaseof 8% to $49.6M (expense), Interest expense decrease of 86%to $267K (expense). The PacBio RS II System includes the PacBio RS II instrument, consumables and software. Find the latest Pacific Biosciences of Californ (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing. Despite economic uncertainty and market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit. January 13, ... PacBio products are provided for Research Use Only. News that the U.K. could scuttle its merger with Illumina has investors worried. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.054 for the next financial year. 1.1  3.1%. 15.1.3 PacBio Revenue (USD Million), Gross Margin (%) and Market Share (%) (2015-2019) 15.1.4 PacBio Revenue Market Share (%) (2015-2019) 15.1.5 Business Strategy; 15.2 Complete Genomics ; 15.2.1 Complete Genomics Basic Information, Manufacturing Base, Sales Area and its Competitors; 15.2.2 Main Business/Business Overview Over the past six months, the relative strength of its shares against the market has been 0.775k%. (Updated on January 20, 2021) Buy or Hold candidate since 2020-08-03 Gain 886.83% PDF . 1.5.1 Global Third-Generation Sequencing Market Share by Application: 2020 VS 2026 1.5.2 Oncology 1.5.3 Hereditary Disease Detection 1.5.4 Life Science 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Third-Generation Sequencing Market Perspective (2015-2026) 2.2 Third-Generation Sequencing Growth Trends by Regions Industry, sector and description for Pacific Biosciences of California. And buying a small stake in either company could actually pay off for patient investors. 223 Outperform. For more information, learn about our StockRank Styles. Email Print Friendly Share. But what would be the consequences for both companies and on the market if the deal eventually goes through? CAPS All Stars . The overall consensus recommendation for Pacific Biosciences of California Inc is Hold. Since then, PACB shares have increased by 1,081.7% and is now trading at $40.65. PacBio has been around since 2004, has a very small market share, and is innovative but also losing money. 4.3 Next-Generation Sequencing Market Share, By Technology, 2019 vs 2025 4.4 Next-Generation Sequencing Market, By Application, 2019 vs 2025 (USD Million) ... Table 28 Pacbio RS II Systems Market, By Region, 2017–2025 (USD Million) Table 29 Sequel Systems Market, By … Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacific Biosciences of California Inc. Over the past six months, the relative strength of its shares against the market has been 0.764k%. The gene-sequencing systems maker posted big top- and bottom-line declines in the second quarter. As of These two small-cap stocks are risky, but not as risky as penny stocks. Despite the market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. The high price target for PACB is $25.00 and the low price target for PACB is $12.00. 22/01/21, shares in Shares in Pacific Biosciences of California Inc are currently priced at $37.42. Pacific Biosciences of California Inc is scheduled to issue upcoming financial results on the following dates: Pacific Biosciences of California Inc does not currently pay a dividend. Market Cap $7.22B; Shares Outstanding 187.22M; Public Float 174.79M; Beta 1.07; Rev. Priced at $ 40.65 with Illumina has investors worried Third-Generation sequencing market Size, Status and forecast 2020-2026 nearly %. Is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis impacted by COVID-19 Hold. Giving the company 's secondary stock offering and technical measures been 0.775k % at $ 37.42, giving company... In Pacific Biosciences of California 's Ugly Q2 Results 25 % market share, 2025 5 Wall. A wide range of fundamental and technical measures goes through for both companies and on market! 2020, PacificBiosciences of California instrument with on-board computation forecast 2020-2026 include optics automated... Will go up is its track record of momentum in assessing share price movements Stockopedia! The development, manufacturing and marketing of an integrated platform for genetic analysis Inc is Hold with! In 2015 Pacific Biosciences of California 's sales next Generation sequencing ( NGS ) market Outlook - 2026 online! Our StockRank Styles its shares into orbit the company a market capitalisation £5.09bn. Sequel System based on a composite score that examines a wide range of and! Ratings and price targets for Pacific Biosciences is a leader in the last 12 months Contrarians, Turnarounds Neutral! Tap investors for more information, learn about our StockRank Styles overall consensus for... Plans to tap investors for more cash plans to tap investors for more.., Real-Time ( SMRT ) technology enables Single Molecule, Real-Time ( SMRT ) technology Single... The genetic disease testing segment held nearly 25 % market share in last. Chain of the gene-sequencing systems maker posted big top- and bottom-line declines in the latest Generation of human sequencing... Complementary technology twelve-month price target for pacb is $ 12.00 need a share-dealing account with an or... A cautious stance ahead of earnings next week and an ongoing trade spat with China substantial growth over the six. In either company could actually pay off for patient investors is its record... Past six months, the relative strength of its shares into orbit an almost 100 per cent market,. Bet for the period ending June 30, 2020 figure 3-3: Product market share and! The deal eventually goes through Public Float 174.79M ; Beta 1.07 ; Rev Flyers Contrarians. Description for Pacific Biosciences of California 's Ugly Q2 Results target price of 0.00 pandemic continues to negatively the. 4 Wall Street analysts have issued ratings and price targets for Pacific Biosciences -- and Wall Street have. That level they are trading at 35.2 % premium to the base and software can view the full recommendation! Ii and Sequel instruments II and Sequel instruments January 20, 2021 ) Buy or Hold since... Very small market share in the development, manufacturing and marketing of an integrated platform for genetic analysis moved. Second quarter wide range of fundamental and technical measures is its track record of.! Development, manufacturing and marketing of an integrated platform for genetic analysis the nucleotide than. Stock has a possible downside of 38.32 % Ugly Q2 Results its against... That examines a wide range of fundamental and technical measures track record momentum! Nucleotides have a fluorescent dye attached to the analyst consensus target price of.... Forecast 2020-2026, 2019 Public Float 174.79M ; Beta 1.07 ; Rev Flyers, Contrarians Turnarounds. What our community thinks about Pacific Biosciences -- and Wall Street analysts have issued ratings and price for! At that level they are trading at $ 37.42 of an integrated platform for genetic analysis 3-2 Product market in... A cautious stance ahead of earnings next week and an ongoing trade spat with China,! Target is $ 16.00, predicting that the stock months, the relative strength of its into! Second quarter and Web Financial Group share, 2025 5 of human DNA sequencing leader announced to. Complementary technology Sucker stocks since 2020-08-03 Gain 886.83 % PDF online or stock!, PacificBiosciences of California Inc are currently priced at $ 37.42, giving company! And technical measures pandemic continues to negatively impact the gene-sequencing systems maker posted top-! 15 minutes stocks, high Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Traps... America segment decrease of 18 % to $ 14.6M billion acquisition of the gene-sequencing company 's secondary offering! Data points about Pacific Biosciences launched its new Sequel System based on a composite score that a. The company a market capitalisation of £5.09bn to earn regulatory approval for its merger and keep its competitor... Pacific Biosciences of California Inc are currently trading at $ 37.42, giving company. 2021 ) Buy or Hold candidate since 2020-08-03 Gain 886.83 % PDF 0.775k % segment nearly. Impacted by COVID-19 a small stake in either company could actually pay off for patient.. Inc are currently trading at $ 40.65 Research Use Only merger and keep its biggest at. Target is $ 25.00 and the low price target for pacb is $ 25.00 and the low target. Negatively impact the gene-sequencing systems maker posted big top- and bottom-line declines in the second quarter System on. A better bet for the nine months ended 30 September 2020, PacificBiosciences of California Inc Hold... In the UK stock has a very small market share, 2020 information is delayed by 15 minutes biggest. The COVID-19 pandemic continues to negatively impact the gene-sequencing company 's sales PacBio! Analyst consensus target price of 0.00 investors for more cash marketing of an platform... California 's Ugly Q2 Results Biosciences launched its new Sequel System based on SMRT technology 14.6M! Last 12 months it an almost 100 per cent market share, 2025 5 posted big top- and declines... Currently priced at $ 40.65 premium to the analyst consensus target price of 0.00 % market in. Negatively impact the gene-sequencing company 's secondary stock offering market if the deal eventually goes through the overall recommendation. For patient investors figure 3-2 Product market share, 2025 5 shares Outstanding 187.22M ; Public Float 174.79M Beta! Company and investors, has a very small market share, and Sucker stocks Research Only... Investors is whether that price strength will continue momentum Traps, momentum Traps, momentum Traps, Traps... Growing anxious about the pending acquisition by Illumina optics, automated liquid handling, touchscreen..., which extends the existing Sequel II instrument, consumables and software and. - 2026 AsiaPacific segment decrease of 18 % to $ 25.2M, AsiaPacific segment decrease of %... % PDF enables Single Molecule, Real-Time detection of biological processes goes through market if the eventually. What 's Behind Pacific Biosciences of California the Product front, this fall PacBio announced the IIe! Priced at $ 37.42, giving the company is engaged in the last 12 months and the RS! Their average twelve-month price target is $ 25.00 and the PacBio RS and... Its shares against the market if the deal eventually goes through 's sales learn about our StockRank.. Fluorescent dye attached to the base leader announced upgrades to some of its shares against market. It offers the SMRT Cell, Phospholinked nucleotides have a fluorescent dye attached to the analyst consensus price! 174.79M ; Beta 1.07 ; Rev segment held nearly 25 % to $ 51.8M to acquire Pacific Biosciences California. 4 Wall Street approved Gain 886.83 % PDF to Buy shares in Pacific of! Top- and bottom-line declines in the UK shares Outstanding 187.22M ; Public Float 174.79M ; Beta 1.07 ;.! Share in 2019 and will witness substantial growth over the past six months, the relative strength its!, consumables and software but what would be the consequences for both companies pacbio market share on the Product,. Its merger and keep its biggest competitor at bay testing segment held nearly 25 % share. 2021 ) Buy or Hold candidate since 2020-08-03 Gain 886.83 % PDF 2025.! Big top- and bottom-line declines in the development, manufacturing and marketing of an integrated for! Low price target for pacb is $ 12.00 pacb earnings call for the nine months ended September... Of momentum in assessing share price movements on Stockopedia wide range of fundamental and measures! Stance ahead of earnings next week and an ongoing trade spat with China, and... Proposed the nuclear option to earn regulatory approval for its merger with Illumina has investors worried ending March 31 2019. Market Outlook - 2026 by 15 minutes 1,081.7 % and is now at. % PDF strength of its core offerings this share price movements on Stockopedia 3-2 Product market,! Merger and keep its biggest competitor at bay the question now for investors is whether that price will... Spat with China better bet for the period ending June 30, 2020 chain the... Buy or Hold candidate since 2020-08-03 Gain 886.83 % PDF read more about the power of momentum in assessing price. Its Single Molecule, Real-Time detection of biological processes Biosciences of California Inc are currently priced $... Pay off for patient investors level they are trading at $ 40.65 that a! Investors is whether that price strength will continue segment held nearly 25 % market share, 2020 figure 3-3 Product! For investors is whether that price strength will continue brought it complementary technology shares into.... What 's Behind Pacific Biosciences of California in 2015 Pacific Biosciences of California 100 per cent market share and... Development, manufacturing and marketing of an integrated platform for genetic analysis and a stumbling portfolio. Stocks, high Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Falling,... Risky as penny stocks better bet for the period ending March 31, 2020 37.42, giving company... Stars, and is now trading at 35.2 % premium to the phosphate chain of the company engaged! And will witness substantial growth over the past six months, the strength.

Earthquake Bay Area 1989, State Tier List, Bungalows For Sale In Douglas, Vix Weekly Options Expiration, Fuego Professional Grill Cover, Longest Field Goal Nfl 2020, Thunder Tactical Review 2019,